# The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

> **NCT07289750** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The Fourth Affiliated Hospital of Zhejiang University School of Medicine** · enrollment: 80 (estimated)

## Conditions studied

- T2DM
- MAFLD

## Interventions

- **DRUG:** alogliptin and actoplus met
- **DRUG:** actoplus met

## Key facts

- **NCT ID:** NCT07289750
- **Lead sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07289750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07289750, "The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07289750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*